In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Horizon Pharma Inc (NASDAQ: HZNP), with a price target of $21. The company’s shares opened today at $20.92, close to its 52-week high of $21.25.
“We rate HZNP as 12-month price target of $21. We continue to believe the rare/orphan disease and rheumatology businesses are underappreciated. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $21. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $21.”
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -7.1% and a 40.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Horizon Pharma Inc with a $22.29 average price target.
The company has a one-year high of $21.25 and a one-year low of $11.17. Currently, Horizon Pharma Inc has an average volume of 1.43M.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Horizon Pharma Plc engages in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo.